Here are three observations:
1. The warrants were issued with private placements that closed prior to Ortho RTi’s shares being listed.
2. An aggregate of 2.11 million warrants earned extensions. They were originally scheduled to expire throughout 2018 and 2019.
3. The extension is for an added year from their respective maturity dates. All other terms of the extended warrants remain unchanged.
More articles on biologics:
3 things to know about Tom Cycyota, AlloSource president & CEO
5 things to know about BioRestorative Therapies
1st patient enrolled in Cerapedics’ TLIF clinical trial: 5 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
